Provention bio announces completion of $35 million equity investment from sanofi us

Companies collaborating to expand access to tzield™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes red bank, n.j. , feb. 13, 2023 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the closing of the $35 million equity investment from sanofi us under the previously announced co-promotion agreement and securities purchase agreement (the "purchase agreement").
PRVB Ratings Summary
PRVB Quant Ranking